Clinical Efficacy of Autologous CIK Cell Adoptive Immunotherapy Combined with Chemotherapy in Patients Withmetastatic Renal Cell Carcinoma

Objective To evaluate the clinical efficacy and safety of autologous CIK cell adoptive immunotherapy combined with chemotherapy in patients with metastatic renal cell carcinoma (mRCC). Methods Ninteen mRCC patients were enrolled and received at least one cycle of 5-fluorouracil/gemcitabine regimen chemotherapy，followed by 4-8 times of CIK cell transfusion and 3 doses(d1~d3) of interleukin-2 (IL -2) and Thymosin α1. Results Among the 19 cases，PR,SD and PD were 1，13 and 5,respectively.Disease control rate (CR+PR+SD) was 73.68%.PFS in 5 patients with PD was 4.43±2.85 months，while PFS in the other 14 cases has reached 11.64 months. Conclusion Our results indicated that autologous CIK cell adoptive immunotherapy combined with chemotherapy has potential benefits and might provide a potent treatment approach for mRCC patients.